Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$201.31 -1.9%	$199.66	$153.58 ▼ $218.66	$356.11B	0.61	5.77 million shs	7.59 million shs
GEHC GE HealthCare Technologies	$72.00 -9.3%	$86.30	$70.49 ▼ $94.80	$32.93B	1.13	2.97 million shs	9.33 million shs
JNJ Johnson & Johnson	$159.90 +2.9%	$159.36	$140.68 ▼ $169.99	$385.33B	0.47	7.76 million shs	13.24 million shs
LLY Eli Lilly and Company	$788.62 -3.6%	$848.85	$711.40 ▼ $972.53	$747.75B	0.34	3.31 million shs	2.67 million shs
MSFT Microsoft	$373.11 -2.4%	$402.24	$367.24 ▼ $468.35	$2.77T	0.92	20.63 million shs	30.13 million shs
NVDA NVIDIA	$101.80 -7.8%	$123.07	$75.61 ▼ $195.95	$2.48T	1.77	312.98 million shs	336.75 million shs
NVO Novo Nordisk A/S	$67.08 -1.7%	$81.64	$66.88 ▼ $148.15	$301.04B	0.42	5.61 million shs	8.82 million shs
PFE Pfizer	$24.30 -1.6%	$25.98	$24.26 ▼ $31.54	$137.79B	0.61	39.30 million shs	53.41 million shs
XLV Health Care Select Sector SPDR Fund	$143.13 -0.8%	$146.51	$135.95 ▼ $159.64	$37.80B	0.71	7.52 million shs	10.98 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.56%	+1.87%	-3.00%	+14.21%	+13.40%
GEHC GE HealthCare Technologies	-0.26%	-2.02%	-8.20%	+1.25%	-9.93%
JNJ Johnson & Johnson	+1.41%	-3.86%	-6.98%	+7.91%	-1.47%
LLY Eli Lilly and Company	+1.97%	-0.88%	-11.90%	+5.33%	+7.28%
MSFT Microsoft	-0.01%	-2.01%	-1.63%	-8.71%	-9.33%
NVDA NVIDIA	+0.25%	-2.94%	-3.19%	-20.16%	+23.44%
NVO Novo Nordisk A/S	+0.29%	-4.94%	-23.73%	-22.07%	-46.07%
PFE Pfizer	+0.84%	-1.84%	-5.65%	-7.07%	-10.24%
XLV Health Care Select Sector SPDR Fund	+0.67%	-0.30%	-3.53%	+4.86%	+0.08%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABBV AbbVie	4.4635 of 5 stars	2.5	3.0	3.3	3.9	3.4	2.5	1.3
GEHC GE HealthCare Technologies	4.1451 of 5 stars	3.4	4.0	1.7	0.0	3.5	1.7	2.5
JNJ Johnson & Johnson	4.3276 of 5 stars	2.3	3.0	4.2	3.9	3.2	2.5	0.6
LLY Eli Lilly and Company	4.9213 of 5 stars	3.4	5.0	3.3	4.0	3.3	2.5	1.9
MSFT Microsoft	4.9083 of 5 stars	4.5	4.0	3.3	2.9	2.8	1.7	1.9
NVDA NVIDIA	4.9105 of 5 stars	4.5	3.0	1.7	3.0	3.2	2.5	2.5
NVO Novo Nordisk A/S	4.821 of 5 stars	4.4	5.0	2.5	0.0	2.6	0.0	4.4
PFE Pfizer	4.9711 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.92	Moderate Buy	$211.45	5.04% Upside
GEHC GE HealthCare Technologies	2.75	Moderate Buy	$97.73	35.73% Upside
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	7.15% Upside
LLY Eli Lilly and Company	2.84	Moderate Buy	$1,009.72	28.04% Upside
MSFT Microsoft	2.90	Moderate Buy	$508.86	36.38% Upside
NVDA NVIDIA	2.95	Moderate Buy	$169.89	66.88% Upside
NVO Novo Nordisk A/S	2.80	Moderate Buy	$145.25	116.52% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	31.40% Upside
XLV Health Care Select Sector SPDR Fund	2.77	Moderate Buy	$143.13	N/A

Current Analyst Ratings Breakdown

Latest NVDA, NVO, ABBV, LLY, XLV, JNJ, MSFT, PFE, and GEHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2025	NVDA NVIDIA	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$120.00
4/2/2025	JNJ Johnson & Johnson	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00 ➝ $181.00
4/2/2025	JNJ Johnson & Johnson	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
4/1/2025	MSFT Microsoft	Westpark Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
3/31/2025	MSFT Microsoft	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$550.00 ➝ $500.00
3/27/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/20/2025	MSFT Microsoft	Tigress Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$550.00 ➝ $595.00
3/20/2025	MSFT Microsoft	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$550.00 ➝ $550.00
3/20/2025	MSFT Microsoft	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$470.00
3/20/2025	NVDA NVIDIA	DA Davidson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$135.00 ➝ $125.00
3/20/2025	NVDA NVIDIA	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$56.33B	6.32	$14.88 per share	13.53	$1.90 per share	105.95
GEHC GE HealthCare Technologies	$19.67B	1.67	$4.52 per share	15.94	$18.51 per share	3.89
JNJ Johnson & Johnson	$88.82B	4.34	$13.14 per share	12.17	$29.69 per share	5.39
LLY Eli Lilly and Company	$45.04B	16.60	$12.86 per share	61.34	$15.05 per share	52.40
MSFT Microsoft	$261.80B	10.59	$13.32 per share	28.01	$40.72 per share	9.16
NVDA NVIDIA	$130.50B	19.03	$0.90 per share	112.93	$1.72 per share	59.19
NVO Novo Nordisk A/S	$290.40B	1.04	$3.11 per share	21.57	$4.64 per share	14.46
PFE Pfizer	$63.63B	2.17	$3.81 per share	6.38	$15.81 per share	1.54
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.28B	$2.40	83.88	14.40	1.62	7.59%	296.28%	12.65%	4/25/2025 (Estimated)
GEHC GE HealthCare Technologies	$1.99B	$4.33	16.63	13.85	3.19	10.13%	25.74%	6.29%	4/29/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$6.65	24.04	14.44	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$11.71	67.35	25.34	1.40	23.51%	85.24%	16.19%	5/1/2025 (Estimated)
MSFT Microsoft	$88.14B	$12.42	30.04	25.38	2.21	35.43%	33.36%	18.07%	4/24/2025 (Estimated)
NVDA NVIDIA	$29.76B	$2.94	40.06	25.58	1.76	55.69%	114.83%	76.61%	5/28/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.29	20.39	14.40	0.90	34.81%	84.68%	26.29%	5/1/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.23	8.02	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
XLV Health Care Select Sector SPDR Fund	N/A	N/A	29.15	∞	N/A	N/A	N/A	N/A	N/A

Latest NVDA, NVO, ABBV, LLY, XLV, JNJ, MSFT, PFE, and GEHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	LLY Eli Lilly and Company	$4.64	N/A	N/A	N/A	$12.77 billion	N/A
5/1/2025	N/A	NVO Novo Nordisk A/S	$0.92	N/A	N/A	N/A	N/A	N/A
4/29/2025	N/A	GEHC GE HealthCare Technologies	$0.91	N/A	N/A	N/A	$4.66 billion	N/A
4/29/2025	N/A	PFE Pfizer	$0.67	N/A	N/A	N/A	$14.43 billion	N/A
4/25/2025	N/A	ABBV AbbVie	$2.51	N/A	N/A	N/A	$12.91 billion	N/A
4/24/2025	N/A	MSFT Microsoft	$3.20	N/A	N/A	N/A	$68.54 billion	N/A
4/15/2025	N/A	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
2/26/2025	Q4 2025	NVDA NVIDIA	$0.84	$0.89	+$0.05	$0.89	$38.16 billion	$39.33 billion
2/13/2025	Q4 2024	GEHC GE HealthCare Technologies	$1.26	$1.45	+$0.19	$1.57	$5.33 billion	$5.32 billion
2/6/2025	Q4 2024	LLY Eli Lilly and Company	$5.45	$5.32	-$0.13	$4.88	$13.42 billion	N/A
2/5/2025	Q4 2024	NVO Novo Nordisk A/S	$0.88	$0.91	+$0.03	$0.91	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.56	3.26%	+6.04%	273.33%	53 Years
GEHC GE HealthCare Technologies	$0.14	0.19%	N/A	3.23%	N/A
JNJ Johnson & Johnson	$4.96	3.10%	+5.43%	74.59%	63 Years
LLY Eli Lilly and Company	$6.00	0.76%	+15.21%	51.24%	11 Years
MSFT Microsoft	$3.32	0.89%	+10.22%	26.73%	23 Years
NVDA NVIDIA	$0.04	0.04%	+33.42%	1.36%	N/A
NVO Novo Nordisk A/S	$1.57	2.34%	+25.26%	47.72%	N/A
PFE Pfizer	$1.72	7.08%	+2.50%	121.99%	16 Years
XLV Health Care Select Sector SPDR Fund	$2.34	1.63%	N/A	N/A	N/A

Latest NVDA, NVO, ABBV, LLY, XLV, JNJ, MSFT, PFE, and GEHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/11/2025	MSFT Microsoft	quarterly	$0.83	0.87%	5/15/2025	5/15/2025	6/12/2025
2/13/2025	ABBV AbbVie	quarterly	$1.64	3.4%	4/15/2025	4/15/2025	5/15/2025
3/27/2025	GEHC GE HealthCare Technologies	quarterly	$0.0350	0.17%	4/25/2025	4/25/2025	5/15/2025
2/5/2025	NVO Novo Nordisk A/S	semi-annual	$0.7874	1.2%	3/31/2025	3/31/2025	4/8/2025
2/26/2025	NVDA NVIDIA	quarterly	$0.01	0.03%	3/12/2025	3/12/2025	4/2/2025
1/9/2025	XLV Health Care Select Sector SPDR Fund		$0.5645		3/24/2025	3/24/2025	3/26/2025
1/9/2025	XLV Health Care Select Sector SPDR Fund		$0.5645		3/24/2025	3/24/2025	3/26/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	17.94	0.66	0.55
GEHC GE HealthCare Technologies	0.88	1.04	0.83
JNJ Johnson & Johnson	0.43	1.11	0.86
LLY Eli Lilly and Company	2.00	1.15	0.97
MSFT Microsoft	0.13	1.35	1.34
NVDA NVIDIA	0.13	4.10	3.64
NVO Novo Nordisk A/S	0.62	0.74	0.55
PFE Pfizer	0.63	1.00	0.73
XLV Health Care Select Sector SPDR Fund	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
GEHC GE HealthCare Technologies	82.06%
JNJ Johnson & Johnson	69.55%
LLY Eli Lilly and Company	82.53%
MSFT Microsoft	71.13%
NVDA NVIDIA	65.27%
NVO Novo Nordisk A/S	11.54%
PFE Pfizer	68.36%
XLV Health Care Select Sector SPDR Fund	N/A

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.08%
GEHC GE HealthCare Technologies	0.27%
JNJ Johnson & Johnson	0.16%
LLY Eli Lilly and Company	0.13%
MSFT Microsoft	0.03%
NVDA NVIDIA	4.23%
NVO Novo Nordisk A/S	0.07%
PFE Pfizer	0.06%
XLV Health Care Select Sector SPDR Fund	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	50,000	1.77 billion	1.76 billion	Optionable
GEHC GE HealthCare Technologies	50,000	457.30 million	456.06 million	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
LLY Eli Lilly and Company	39,000	948.17 million	948.08 million	Optionable
MSFT Microsoft	228,000	7.43 billion	7.43 billion	Optionable
NVDA NVIDIA	26,200	24.40 billion	23.45 billion	Optionable
NVO Novo Nordisk A/S	54,400	4.49 billion	4.48 billion	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
XLV Health Care Select Sector SPDR Fund	N/A	264.07 million	N/A	Not Optionable

NVDA, NVO, ABBV, LLY, XLV, JNJ, MSFT, PFE, and GEHC Headlines

Recent News About These Companies

Consumer staples Q1 roundup: Philip Morris tops chart, Target worse performer

April 2 at 7:47 AM | msn.com

Solventum Stock: Is SOLV Outperforming the Healthcare Sector?

April 2 at 7:47 AM | msn.com

Be Smart This April Fool's Day: Buy Market-Beating ETFs of Q1

April 1 at 11:00 AM | zacks.com

Waters Corporation Stock: Is WAT Outperforming the Healthcare Sector?

March 26, 2025 | msn.com

Health Care Select Sector SPDR Fund (NYSEARCA:XLV) Stock Price Passes Below Two Hundred Day Moving Average - Time to Sell?

March 26, 2025 | americanbankingnews.com

S&P sector rankings as the first quarter of 2025's close is around the corner

March 24, 2025 | msn.com

3 Sector ETFs & Stocks to Gain Despite Downbeat February Jobs Data

March 14, 2025 | zacks.com

Merck and 8 More Healthcare Stocks for Nervous Dividend Investors

March 13, 2025 | msn.com

Select Sector SPDR ETFs: Strategic Investment with Sector-Specific Allocations

March 12, 2025 | finance.yahoo.com

Recession Fears Looming? Secure Your Portfolio With These ETFs

March 11, 2025 | zacks.com

Health Care Sector Trying to Bounce Back

March 6, 2025 | theglobeandmail.com

Shifting Tides in Leadership: Markets Play Defense

March 6, 2025 | etftrends.com

Time for Defensive Sector ETFs?

February 27, 2025 | zacks.com

Healthcare best performing sector as market angst builds

February 25, 2025 | marketwatch.com

Healthcare Stocks Should Be Hurting. How the Sector Became This Year’s Top Performer.

February 25, 2025 | msn.com

Health Care Has Been a Top Sector

February 22, 2025 | finance.yahoo.com

What Top-Performing Healthcare Funds Are Buying Now

February 19, 2025 | msn.com

Final Trade: FWONK, XLV, MSFT, PEP

February 13, 2025 | youtube.com

18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard

February 8, 2025 | msn.com

Financials, Health Care Sectors Leading U.S. Stocks Higher In 2025

February 7, 2025 | seekingalpha.com

S&P 500 Earnings Set to Shine: January's Critical Market Test (XLV)

December 27, 2024 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
NVIDIA Insiders Sell: This Is What It Means for the Market
By Thomas Hughes | March 25, 2025
View NVIDIA Insiders Sell: This Is What It Means for the Market
Intel Foundry’s Moment of Truth: Will 18A Deliver?
By Jeffrey Neal Johnson | March 6, 2025
View Intel Foundry’s Moment of Truth: Will 18A Deliver?
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
By Chris Markoch | March 23, 2025
View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
Missed the Hims & Hers Rally? Clover Health Could Be Next
By Gabriel Osorio-Mazilli | March 5, 2025
View Missed the Hims & Hers Rally? Clover Health Could Be Next

NVDA, NVO, ABBV, LLY, XLV, JNJ, MSFT, PFE, and GEHC Company Descriptions

AbbVie NYSE:ABBV

$201.31 -3.88 (-1.89%)

Closing price 03:59 PM Eastern

Extended Trading

$201.59 +0.28 (+0.14%)

As of 06:27 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

GE HealthCare Technologies NASDAQ:GEHC

$72.00 -7.36 (-9.27%)

Closing price 04:00 PM Eastern

Extended Trading

$71.45 -0.55 (-0.76%)

As of 06:27 PM Eastern

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Johnson & Johnson NYSE:JNJ

$159.90 +4.54 (+2.92%)

Closing price 03:59 PM Eastern

Extended Trading

$159.00 -0.89 (-0.56%)

As of 06:27 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Eli Lilly and Company NYSE:LLY

$788.62 -29.60 (-3.62%)

Closing price 03:59 PM Eastern

Extended Trading

$788.38 -0.24 (-0.03%)

As of 06:27 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Microsoft NASDAQ:MSFT

$373.11 -9.03 (-2.36%)

Closing price 04:00 PM Eastern

Extended Trading

$370.52 -2.59 (-0.69%)

As of 06:27 PM Eastern

Microsoft Corporation develops and supports software, services, devices and solutions worldwide. The Productivity and Business Processes segment offers office, exchange, SharePoint, Microsoft Teams, office 365 Security and Compliance, Microsoft viva, and Microsoft 365 copilot; and office consumer services, such as Microsoft 365 consumer subscriptions, Office licensed on-premises, and other office services. This segment also provides LinkedIn; and dynamics business solutions, including Dynamics 365, a set of intelligent, cloud-based applications across ERP, CRM, power apps, and power automate; and on-premises ERP and CRM applications. The Intelligent Cloud segment offers server products and cloud services, such as azure and other cloud services; SQL and windows server, visual studio, system center, and related client access licenses, as well as nuance and GitHub; and enterprise services including enterprise support services, industry solutions, and nuance professional services. The More Personal Computing segment offers Windows, including windows OEM licensing and other non-volume licensing of the Windows operating system; Windows commercial comprising volume licensing of the Windows operating system, windows cloud services, and other Windows commercial offerings; patent licensing; and windows Internet of Things; and devices, such as surface, HoloLens, and PC accessories. Additionally, this segment provides gaming, which includes Xbox hardware and content, and first- and third-party content; Xbox game pass and other subscriptions, cloud gaming, advertising, third-party disc royalties, and other cloud services; and search and news advertising, which includes Bing, Microsoft News and Edge, and third-party affiliates. The company sells its products through OEMs, distributors, and resellers; and directly through digital marketplaces, online, and retail stores. The company was founded in 1975 and is headquartered in Redmond, Washington.

NVIDIA NASDAQ:NVDA

$101.80 -8.62 (-7.81%)

Closing price 04:00 PM Eastern

Extended Trading

$102.18 +0.38 (+0.38%)

As of 06:27 PM Eastern

NVIDIA Corporation provides graphics and compute and networking solutions in the United States, Taiwan, China, Hong Kong, and internationally. The Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; virtual GPU or vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building and operating metaverse and 3D internet applications. The Compute & Networking segment comprises Data Center computing platforms and end-to-end networking platforms, including Quantum for InfiniBand and Spectrum for Ethernet; NVIDIA DRIVE automated-driving platform and automotive development agreements; Jetson robotics and other embedded platforms; NVIDIA AI Enterprise and other software; and DGX Cloud software and services. The company's products are used in gaming, professional visualization, data center, and automotive markets. It sells its products to original equipment manufacturers, original device manufacturers, system integrators and distributors, independent software vendors, cloud service providers, consumer internet companies, add-in board manufacturers, distributors, automotive manufacturers and tier-1 automotive suppliers, and other ecosystem participants. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.

Novo Nordisk A/S NYSE:NVO

$67.08 -1.16 (-1.70%)

Closing price 03:59 PM Eastern

Extended Trading

$66.97 -0.11 (-0.16%)

As of 06:27 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer NYSE:PFE

$24.30 -0.41 (-1.64%)

Closing price 03:59 PM Eastern

Extended Trading

$24.28 -0.02 (-0.08%)

As of 06:27 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Health Care Select Sector SPDR Fund NYSEARCA:XLV

$143.13 -1.17 (-0.81%)

Closing price 04:10 PM Eastern

Extended Trading

$142.60 -0.53 (-0.37%)

As of 06:23 PM Eastern

Health Care Select Sector SPDR Fund (the Fund) seeks to closely match the returns and characteristics of the S&P Health Care Select Sector Index (the Index). The companies included in the Index are selected on the basis of general industry classification from a universe of companies defined by the Standard & Poor's 500 Composite Stock Index (S&P 500). The Health Care Select Sector Index includes companies from the industries, such as pharmaceuticals, healthcare providers and services, healthcare equipment and supplies, biotechnology, life sciences tools and services, and healthcare technology. Under normal market conditions, the Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the Index. State Street Global Advisors acts as the Fund's investment manager.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVDA, NVO, ABBV, LLY, XLV, JNJ, MSFT, PFE, and GEHC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVDA, NVO, ABBV, LLY, XLV, JNJ, MSFT, PFE, and GEHC Earnings

Compare Dividends

Latest NVDA, NVO, ABBV, LLY, XLV, JNJ, MSFT, PFE, and GEHC Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVDA, NVO, ABBV, LLY, XLV, JNJ, MSFT, PFE, and GEHC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NVDA, NVO, ABBV, LLY, XLV, JNJ, MSFT, PFE, and GEHC Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools